MONOCLONAL ANTIBODY ELIGIBILITY CRITERIA CHECKLIST (ALSO APPENDIX 3J)

Several monoclonal antibodies have received emergency use authorization from the FDA for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Resident Name:		Date:
InclusionCriteria (Must Meet All 3 Criteria)		No
Mild to moderately symptomatic COVID-191		
Within 10 days of symptom onset, preferably in the first 3 days		
Positive direct test for SARS-CoV-2 (either A or B) A) If no outbreak present in the building, PCR positive B) If outbreak is present in the building, PCR or antigen positive		
High Risk Criteria forAdults (Must Have 1 of the Following)	Yes	No
Body mass index ≥ 35		
Age ≥ 65		
Chronic kidney disease		
Diabetes		
Immunosuppressive disease or currently receiving immunosuppressive treatment		
≥ 55 years of age AND have: · Cardiovascular disease, OR · Hypertension, OR · Chronic obstructive pulmonary disease/other chronic respiratory disease		
Exclusion Criteria (May Not Have Any of the Following)	Yes	No
Patient is hospitalized or meets hospitalization criteria ²		
Patient requires oxygen due to COVID-19 (Pulse ox ≤ 93% on room air)		
If on chronic oxygen, patient requires an increase in oxygen therapy due to COVID-19		
Patient is on hospice, is hospice eligible, had a palliative care/hospice consult within the prior 6 months, or has a life expectancy less than 6 months (clinician judgement or MDS J1400), inclusions of these residents can be decided on a case by case basis		

DEFINITIONS		
Mild to Moderate Symptoms (1 or more of the following)	Hospitalization Criteria Definition (1 or more of the following)	
 Fever (99.0 or greater) New cough Sore throat Malaise Headaches Muscle pain/aches Gastrointestinal symptoms Shortness of breath with exertion Loss of smell and taste 	 RR≥30 HR ≥ 130 SBP < 90 despite fluid resuscitation 	